


Registered number
3030237

AA PHARMA EUROPE LIMITED

Report and Accounts

31 March 2012

MONDAY



A1L2FR1T

A22

05/11/2012

#63

COMPANIES HOUSE

AA PHARMA EUROPE LIMITED
Report and accounts
Contents

	Page
Director's report	1
Profit and loss account	2
Balance sheet	3
Notes to the accounts	4-6

AA PHARMA EUROPE LIMITED**Registered number: 3030237****Director's Report**

The director presents her report and accounts for the year ended 31 March 2012

Principal activities

The company's principal activity during the year continued to be that of consultants to the healthcare sector

Directors

The following persons served as directors during the year

M Stratford-Bobbitt

Director's responsibilities

The director is responsible for preparing the report and accounts in accordance with applicable law and regulations

Company law requires the director to prepare accounts for each financial year. Under that law the director has elected to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these accounts, the director is required to

- select suitable accounting policies and then apply them consistently,
- make judgements and estimates that are reasonable and prudent,
- prepare the accounts on the going concern basis unless it is inappropriate to presume that the company will continue in business

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable her to ensure that the accounts comply with the Companies Act 2006. She is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small company provisions

This report has been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

This report was approved by the board on 11 October 2012 and signed on its behalf



M Stratford-Bobbitt
Director

AA PHARMA EUROPE LIMITED
Profit and Loss Account
for the year ended 31 March 2012

	Notes	2012 £	2011 £
Turnover		66,970	64,861
Administrative expenses		(55,393)	(48,187)
Other operating income		10	6
Operating profit	2	<u>11,587</u>	<u>16,680</u>
Profit on ordinary activities before taxation		<u>11,587</u>	<u>16,680</u>
Tax on profit on ordinary activities	3	(2,274)	(3,497)
Profit for the financial year		<u>9,313</u>	<u>13,183</u>

AA PHARMA EUROPE LIMITED
Balance Sheet
as at 31 March 2012


	Notes	2012 £	2011 £
Current assets			
Debtors	5	14,175	5,918
Cash at bank and in hand		<u>4,286</u>	<u>14,447</u>
		18,461	20,365
Creditors: amounts falling due within one year	6	(18,459)	(20,363)
Net current assets		<u>2</u>	<u>2</u>
Net assets		<u>2</u>	<u>2</u>
Capital and reserves			
Called up share capital	7	2	2
Shareholders' funds		<u>2</u>	<u>2</u>

The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006

Members have not required the company to obtain an audit in accordance with section 476 of the Act

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts

The accounts have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime



M Stratford-Bobbitt
 Director

Approved by the board on 11 October 2012

AA PHARMA EUROPE LIMITED
Notes to the Accounts
for the year ended 31 March 2012

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

Turnover

Turnover represents the amount of services sold net of Value Added Tax. All the turnover and pre tax profit is generated in the UK from the principal activity of the business.

Depreciation

Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:

Office Equipment	20% straight line
------------------	-------------------

Pensions

The company operates a defined contribution pension scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme. There are no contributions outstanding or repaid at the balance sheet date.

2 Operating profit	2012	2011
	£	£
This is stated after charging:		
Directors' remuneration	6,795	5,700
Pension costs	3,790	-
	<hr/>	<hr/>
3 Taxation	2012	2011
	£	£
UK corporation tax	2,274	3,497
	<hr/>	<hr/>

4 Tangible fixed assets

	Office Equipment £
Cost	
At 1 April 2011	12,801
At 31 March 2012	<hr/> 12,801
Depreciation	
At 1 April 2011	12,801
At 31 March 2012	<hr/> 12,801
Net book value	
At 31 March 2012	<hr/> -

AA PHARMA EUROPE LIMITED
Notes to the Accounts
for the year ended 31 March 2012

5 Debtors			2012	2011
			£	£
Trade debtors			5,686	5,918
Other debtors			8,489	-
			<u>14,175</u>	<u>5,918</u>
6 Creditors: amounts falling due within one year			2012	2011
			£	£
Corporation tax			2,300	3,500
Other taxes and social security costs			13,159	13,717
Other creditors			3,000	3,146
			<u>18,459</u>	<u>20,363</u>
7 Share capital	Nominal value	2012 Number	2012	2011
			£	£
Allotted, called up and fully paid				
Ordinary shares	£1 each	2	<u>2</u>	<u>2</u>
8 Profit and loss account			2012	
			£	
Profit for the year			9,313	
Dividends			(9,313)	
			<u>-</u>	
At 31 March 2012				
9 Dividends			2012	2011
			£	£
Dividends for which the company became liable during the year				
Dividends paid			<u>9,313</u>	<u>13,183</u>
10 Loans to directors				
Description and conditions	B/fwd	Paid	Repaid	C/fwd
	£	£	£	£
M Stratford-Bobbitt				
Interest free loan	(147)	31,737	(23,101)	8,489
	<u>(147)</u>	<u>31,737</u>	<u>(23,101)</u>	<u>8,489</u>

AA PHARMA EUROPE LIMITED
Notes to the Accounts
for the year ended 31 March 2012

11 Related party transactions

M Stratford-Bobbitt

Director

Dividends of £9,313 (2011 £13,183) were paid to the director

12 Ultimate controlling party

The ultimate controlling party is M Stratford-Bobbitt